<DOC>
	<DOCNO>NCT02598219</DOCNO>
	<brief_summary>The aim study evaluate sentinel node policy early stage endometrial carcinoma intermediate high risk recurrence ( compare sentinel node policy current French initial staging protocol ) .</brief_summary>
	<brief_title>Evaluation Sentinel Node Policy Early Stage Endometrial Carcinomas Intermediate High Risk Recurrence .</brief_title>
	<detailed_description>1 . Routine exam require diagnosis : - Endometrioid biopsy product dilatation-curettage hysteroscopy diagnosis histologic type - Tumor assessment : Lombopelvic MRI ( 1.5 3T ) gadolinium injection , study steady dynamic sequence . US CT-Scan case intolerance MRI discuss . FDG-PET may option . 2 . Tumor board : The complete chart review confirm risk group indication . 3 . Complete physical gynecological examination surgical oncologist follow consultation anesthesiology confirm operability patient . 4 . Informed signed consent form . 5 . Study baseline assessment . Then , 6 . Randomization surgery perform accord arm within maximum 4 week first consultation . Arm A : Sentinel node policy* Arm B : - Bilateral pelvic lymphadenectomy ( intermediate risk endometrioid ) - Or Ilio-infrarenal paraaortic lymphadenectomy ( high risk endometrioid ) - Or Pelvic + paraaortic lymphadenectomies ( high risk non endometrioid ) * - along peritoneal stag arm ( cytology , random biopsy , infracolic omentectomy ) 7 . Second tumor board : definitive pathological result hysterectomy-annexectomy node ( sentinel ) specimens .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<criteria>1 . Patients early endometrial carcinoma early FIGO clinical stage III ( clinical examination , abdominopelvic MRI/Ultrasound CT scan MRI possible endometrial biopsy curettage ) , stratification recurrence risk define European Society Medical Oncology ( ESMO ) : Intermediaterisk endometrioid ( type 1 ) : 2009 FIGO stage IA/T1a grade 3 , IBII grade 1 2 Or High risk endometrioid ( type 1 ) : 2009 FIGO stage IB/T1b II , grade 3 Or High risk non endometrioid ( type 2 ) : 2009 FIGO stage III 2 . Without suspicious pelvic , paraaortic , distant node preoperative MRI 3 . Age ≥ 18 year 4 . Performance status ( OMS ) ≤ 2 5 . No contraindication surgery 6 . Absence known hypersensitivity colloidal rhenium sulphide technetium ( nanocolloid ) one excipients , injectable dye ( blue dye indocyanine green available ) one excipients , triphenylmethane derivative 7 . Signed date informed consent 8 . Effective contraception patient reproductive potential 9 . Patient affiliate health insurance system 1 . Preoperative workup : Previous hysterectomy ( nature , trial offer secondary staging procedure ) non carcinoma ( example sarcoma , trophoblastic tumor ) Lowrisk endometrioid carcinoma define ESMO : 2009 FIGO stage IA grade 12 Metastatic disease Suspicious adenopathy preoperative workup 2 . Pregnant and/or breastfeed woman 3 . No comprehension trial 4 . Patient deprive liberty guardianship 5 . Inexperience pelvic sentinel node detection</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Sentinel node</keyword>
</DOC>